NuVasive, Inc.

NasdaqGS:NUVA Rapporto sulle azioni

Cap. di mercato: US$2.1b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NuVasive Crescita futura

Future criteri di controllo 3/6

NuVasive is forecast to grow earnings and revenue by 46.2% and 6.7% per annum respectively. EPS is expected to grow by 44.6% per annum. Return on equity is forecast to be 14.3% in 3 years.

Informazioni chiave

46.2%

Tasso di crescita degli utili

44.6%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili17.4%
Tasso di crescita dei ricavi6.7%
Rendimento futuro del capitale proprio14.3%
Copertura analitica

Good

Ultimo aggiornamento01 Sep 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31
NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13
These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Sep 22
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Sep 01
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Aug 17

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Aug 11
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30
At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02
Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21
NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29
Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18
At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17
Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30
Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12
Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09
Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16
Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05
What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:NUVA - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20251,452911142898
12/31/20241,3607310723312
12/31/20231,279386321412
6/30/20231,22628-3140N/A
3/31/20231,2192023165N/A
12/31/20221,2024030169N/A
9/30/20221,199-2027160N/A
6/30/20221,174-4044171N/A
3/31/20221,159-3738157N/A
12/31/20211,139-6470182N/A
9/30/20211,129-26103217N/A
6/30/20211,1532122232N/A
3/31/20211,062-50107212N/A
12/31/20201,051-3776186N/A
9/30/20201,069-978188N/A
6/30/20201,065-462175N/A
3/31/20201,1536196216N/A
12/31/20191,16865105235N/A
9/30/20191,14648104229N/A
6/30/20191,12752115235N/A
3/31/20191,1164989207N/A
12/31/20181,10212110219N/A
9/30/20181,08524109209N/A
6/30/20181,0604184187N/A
3/31/20181,0384277185N/A
12/31/20171,0278264177N/A
9/30/20171,0276465179N/A
6/30/20171,0193517123N/A
3/31/201799653N/A127N/A
12/31/201696237N/A158N/A
9/30/201690642N/A137N/A
6/30/201686751N/A154N/A
3/31/201683431N/A120N/A
12/31/201581166N/A89N/A
9/30/201580062N/A67N/A
6/30/201579047N/A102N/A
3/31/201577733N/A118N/A
12/31/2014762-17N/A116N/A
9/30/2014749-18N/A124N/A
6/30/2014728-9N/A113N/A
3/31/2014703-11N/A97N/A
12/31/20136858N/A97N/A
9/30/2013660-1N/A101N/A
6/30/2013639-6N/A97N/A
3/31/20136283N/A114N/A
12/31/20126203N/A130N/A
9/30/2012605-4N/A109N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: NUVA's forecast earnings growth (46.2% per year) is above the savings rate (2.2%).

Guadagni vs Mercato: NUVA's earnings (46.2% per year) are forecast to grow faster than the US market (14.9% per year).

Guadagni ad alta crescita: NUVA's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: NUVA's revenue (6.7% per year) is forecast to grow slower than the US market (8.1% per year).

Ricavi ad alta crescita: NUVA's revenue (6.7% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: NUVA's Return on Equity is forecast to be low in 3 years time (14.3%).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y